A short course of caplacizumab rapidly restored platelet levels in a patient with plasma-exchange-refractory immune-mediated thrombotic thrombocytopenic purpura, according to a case report and focused literature review published by clinicians in mainland China. While caplacizumab has transformed the management of acute immune-mediated thrombotic thrombocytopenic purpura internationally, clinical experience with the agent in mainland China has remained limited.
The case report details the clinical trajectory of a 53-year-old woman presenting with Sjögren’s disease and acute immune-mediated thrombotic thrombocytopenic purpura complicated by cerebral infarctions. Initial management consisted of corticosteroids, two early doses of rituximab, and more than ten sessions of therapeutic plasma exchange. Despite these standard interventions, the patient failed to achieve a sustained platelet response, satisfying traditional clinical criteria for therapeutic plasma exchange-refractory disease.
Following the failure of frontline therapy, clinicians administered five daily doses of caplacizumab. The treatment prompted a rapid hematologic response, with the patient’s platelet count rising sharply to 631 × 10⁹/L. Subsequent caplacizumab doses were withheld due to clinical safety concerns regarding the marked platelet increase, alongside the unavailability of additional drug supplies.
Therapeutic plasma exchange was also terminated following the caplacizumab course due to a plasma shortage. Laboratory monitoring demonstrated that the patient’s ADAMTS13 activity reached 72.73% during therapeutic plasma exchange but dropped below 10% after exchange cessation. After administering two additional doses of rituximab, the patient’s ADAMTS13 activity recovered, and she maintained clinical remission through September 2026, encompassing 18 months of post-discharge follow-up.
Alongside the patient report, the authors conducted a focused review of adult patients with immune-mediated thrombotic thrombocytopenic purpura treated with therapeutic plasma exchange and immunosuppressive therapy. Their evaluation revealed that successful early discontinuation of caplacizumab was most consistently associated with serial ADAMTS13 recovery.
The authors noted that although the patient’s clinical course is consistent with a rapid platelet response following the addition of caplacizumab to standard treatment, the case does not establish that a short course is sufficient or that it reduces bleeding risk. In healthcare settings facing restricted drug access or reimbursement constraints, the authors concluded that shorter courses warrant prospective evaluation alongside standard immunosuppression, serial ADAMTS13 monitoring, close clinical surveillance, and access to rescue therapy.
The case report and literature synthesis, published in Frontiers in Cardiovascular Medicine under the Thrombosis and Haemostasis section, was authored by Xiaoyan Huang, Ling Wu, and Lijun Zhang. The clinicians, affiliated with Shenzhen Hospital at The University of Hong Kong and the Shenzhen Clinical Research Center for Rare Diseases, documented an early clinical application of caplacizumab in mainland China that preceded another detailed report from the region.
Subject of Research: Caplacizumab treatment for refractory immune-mediated thrombotic thrombocytopenic purpura
Article Title: Case Report: Early Chinese experience with caplacizumab for plasma-exchange-refractory immune-mediated TTP and a focused review of short-course treatment
Article References: Huang, X., Wu, L., & Zhang, L. (2026). Case Report: Early Chinese experience with caplacizumab for plasma-exchange-refractory immune-mediated TTP and a focused review of short-course treatment. Frontiers in Cardiovascular Medicine, 13, Article 2020504. https://doi.org/10.3389/fcvm.2026.2020504
Image Credits: AI Generated
DOI: 10.3389/fcvm.2026.2020504
Keywords: Caplacizumab, Immune-mediated thrombotic thrombocytopenic purpura, ADAMTS13 activity, Therapeutic plasma exchange, Sjögren's disease, Rituximab, Platelet response, Cerebral infarction, Corticosteroids, TPE-refractory disease, Short-course treatment, Plasma shortage, Clinical remission, Serial ADAMTS13 monitoring, Shenzhen Hospital, Thrombosis and haemostasis, Rare diseases
News Source: Ophelia Keating. (November 11, 2026). Platelet Count Rose Rapidly After Caplacizumab in Refractory iTTP Case. Scienmag.



